We are live on ! Find out more
D.E. Shaw & Co

D.E. Shaw & Co Portfolio holdings

AUM $166B
1-Year Est. Return 43.98%
 

D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.

This Fund
S&P 500
This Quarter Est. Return
-14.3%
1 Year Est. Return
+43.98%
3 Year Est. Return
+138.44%
5 Year Est. Return
+164.23%
10 Year Est. Return
+713.02%
AUM
$85.3B
AUM Growth
-$21.5B
Cap. Flow
-$8.24B
Cap. Flow %
-9.67%
Top 10 Hldgs %
8.52%
Holding
6,080
New
596
Increased
1,780
Reduced
1,836
Closed
791

Sector Composition

Rank Sector Weight
1 Technology 12.38%
2 Financials 10.31%
3 Healthcare 7.77%
4 Consumer Discretionary 7.11%
5 Industrials 5.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLSI icon
4476
Greenwich LifeSciences
GLSI
$197M
$149K ﹤0.01%
+17,631
New +$202K
MERC icon
4477
Mercer International
MERC
$44.7M
$149K ﹤0.01%
11,347
-42,865
-79% -$635K
MCRB icon
4478
Seres Therapeutics
MCRB
$47M
$148K ﹤0.01%
2,157
-2,625
-55% -$226K
DRIO icon
4479
DarioHealth
DRIO
$54.6M
$147K ﹤0.01%
1,196
+653
+120% +$76.6K
SABR icon
4480
CALL
Sabre
SABR
$704M
$147K ﹤0.01%
25,300
HBIO icon
4481
Harvard Bioscience
HBIO
$27M
$146K ﹤0.01%
+4,069
New +$184K
CANO.WS
4482
DELISTED
Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150
CANO.WS
$146K ﹤0.01%
+215,000
New +$223K
ROIVW
4483
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$146K ﹤0.01%
+242,918
New +$127K
RFL icon
4484
Rafael Holdings
RFL
$119M
$145K ﹤0.01%
78,559
-19,424
-20% -$38.7K
RUMBW
4485
RUM Group Inc Warrant
RUMBW
$13M
$145K ﹤0.01%
107,072
ANNX icon
4486
Annexon
ANNX
$841M
$144K ﹤0.01%
38,326
-125,053
-77% -$382K
APYX icon
4487
Apyx Medical
APYX
$164M
$144K ﹤0.01%
+24,586
New +$126K
OPTU
4488
CALL
Optimum Communications Inc
OPTU
$298M
$144K ﹤0.01%
15,600
-48,600
-76% -$509K
CBIO
4489
Crescent Biopharma
CBIO
$626M
$144K ﹤0.01%
2,420
-137
-5% -$10.1K
CAAP icon
4490
Corporacion America
CAAP
$4.28B
$143K ﹤0.01%
25,623
+8,338
+48% +$51.5K
FPH icon
4491
Five Point Holdings
FPH
$385M
$143K ﹤0.01%
36,650
-5,828
-14% -$30.1K
GHY
4492
PGIM Global High Yield Fund
GHY
$479M
$143K ﹤0.01%
12,500
TNYA icon
4493
Tenaya Therapeutics
TNYA
$167M
$143K ﹤0.01%
25,440
-13,076
-34% -$106K
NUTX
4494
Nutex Health
NUTX
$1.02B
$141K ﹤0.01%
+292
New +$344K
WHWK
4495
Whitehawk Therapeutics
WHWK
$183M
$140K ﹤0.01%
+11,395
New +$169K
SILV
4496
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
$140K ﹤0.01%
22,900
-1,993
-8% -$15.1K
FUV
4497
DELISTED
Arcimoto, Inc. Common Stock
FUV
$140K ﹤0.01%
2,146
-101
-4% -$8.01K
HIO
4498
Western Asset High Income Opportunity Fund
HIO
$334M
$139K ﹤0.01%
35,000
PRCH icon
4499
Porch Group
PRCH
$1.39B
$139K ﹤0.01%
54,111
+42,679
+373% +$177K
TKC icon
4500
Turkcell
TKC
$4.79B
$137K ﹤0.01%
54,723
+235
+0.4% +$760

Similar funds

D.E. Shaw & Co's Q2 2022 Portfolio in Review

As of Q2 2022, D.E. Shaw & Co held 6,080 positions worth $85.3B, down 20% from $107B the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.

D.E. Shaw & Co withdrew a net $8.24B in Q2 2022, closing 791 positions and reducing 1,836 holdings. Its most notable exit was Dominion Energy, Inc. 2019 Series A Corporate Units, an estimated $64.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 14% a quarter earlier, followed by Financials and Healthcare.

Against the trend, D.E. Shaw & Co opened a new position in iShares MSCI Emerging Markets ETF worth $171M.

  • D.E. Shaw & Co's largest Q2 2022 buy was iShares MSCI Emerging Markets ETF: 4,273,656 shares worth $171M.
  • D.E. Shaw & Co added most to iShares iBoxx $ Investment Grade Corporate Bond ETF in Q2 2022, an estimated $510M increase.
  • D.E. Shaw & Co's biggest Q2 2022 reduction was Marathon Petroleum, cutting an estimated $573M.
  • D.E. Shaw & Co fully exited Dominion Energy, Inc. 2019 Series A Corporate Units in Q2 2022, selling an estimated $64.1M.
  • D.E. Shaw & Co's ten largest holdings make up 8.5% of its $85.3B portfolio in Q2 2022.
  • D.E. Shaw & Co opened 596 new positions and closed 791 in Q2 2022.
  • D.E. Shaw & Co's portfolio value fell 20% quarter-over-quarter to $85.3B.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.